Dr. Eran R. Andrechek

Email: eranandrechek@gmail.com

Qualifications

1997 B.Sc., McMaster University, Molecular Biology and Biotechnology

Publications (Selected)

1. T58A Myc induced tumors have reduced dependency upon Kras mutations and initiate tumors with similarities to human-claudin low breast cancer. Hollern, D., Yuwanita, I. and E.R. Andrechek.
2. Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity. Broeker CD, Ortiz MMO, Murillo MS, Andrechek ER. Breast Cancer Res. 2023;25(1):120. Published 2023 Oct 7. doi:10.1186/s13058-023-01723-3
3. Molecular Characterization and Landscape ofBreast cancer Models from a multi-omics Perspective. Ortiz MMO, Andrechek ER. J Mammary Gland Biol Neoplasia. 2023;28(1):12. Published 2023 Jun 3. doi:10.1007/s10911-023-09540-2
4. Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH. Swiatnicki MR, Rennhack JP, Ortiz MMO, et al. PLoS Genet. 2022;18(9):e1010362. Published 2022 Sep 2. doi:10.1371/journal.pgen.1010362
5. Metastasis is altered through multiple processes regulated by the E2F1 transcription factor. Swiatnicki MR, Andrechek ER. Sci Rep. 2021;11(1):9502. Published 2021 May 4. doi:10.1038/s41598-021-88924-y
6. Low E2F2 activity is associated with high genomic instability and PARPi resistance. Rennhack JP, Andrechek ER. Sci Rep. 2020;10(1):17948. Published 2020 Oct 21. doi:10.1038/s41598-020-74877-1
7. Functional Redundancy between β1 and β3 Integrin in Activating the IR/Akt/mTORC1 Signaling Axis to Promote ErbB2-Driven Breast Cancer. Bui T, Rennhack J, Mok S, et al. Cell Rep. 2019;29(3):589-602.e6. doi:10.1016/j.celrep.2019.09.004
8. Identification of an Unfavorable Immune Signature in Advanced Lung Tumors from Nrf2-Deficient Mice. Zhang D, Rennhack J, Andrechek ER, Rockwell CE, Liby KT. Antioxid Redox Signal. 2018;29(16):1535-1552. doi:10.1089/ars.2017.7201
9. Triple-negative breast cancer and the potential for targeted therapy. Jhan JR, Andrechek ER. Pharmacogenomics. 2017;18(17):1595-1609. doi:10.2217/pgs-2017-0117
10. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Lunt SY, Muralidhar V, Hosios AM, et al. Mol Cell. 2015;57(1):95-107. doi:10.1016/j.molcel.2014.10.027
11. A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer. Hollern DP, Yuwanita I, Andrechek ER. Oncogene. 2013;32(10):1296-1304. doi:10.1038/onc.2012.142
    
12. Prediction and Genetic Demonstration of a Role for Activator E2Fs in Myc Induced TumorsKenichiro Fujiwara, Inez Yuwanita, Daniel Hollern and Eran R. Andrechek Cancer Research, e-pub January 18, 2011 DOI: 10.1158/0008-5472. CAN-10-2386
13. Mouse Models of Cancers: Opportunities to Address Heterogeneity of Human Cancer and Evaluate Therapeutic Strategies. E.R. Andrechek and J.R. Nevins, Journal of Molecular Medicine, e-pub 24 June 2010 DOI: 10.1007/s00109-010-0644-z
14. Heterogeneity in MYC-Induced Mammary Tumors Determines Outcomes Following Loss of Myc Activity J.Y. Leung, E.R. Andrechek, R. D.Cardiff, and J.R. Nevins Under Review at Oncogene, 8/30/2011
15. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. E. R. Andrechek, R.D. Cardiff, J.T. Chang, M.L. Gatza, A. Potti, and J. R. NevinsPNAS 2009 106:16387-16392; published online before print September 4, 2009
16. A Role for E2F Activities in Determining the Fate of Myc-Induced Lymphomagenesis
17. R.E. Rempel, S. Mori, M. Gasparetto, M.A. Glozak, E.R. Andrechek, S.B. Adler, N. Laakso, A.S. Lagoo, R. Storms, C. Smith and J.R. Nevins PLOS GENETICS, 2009 Sep;5(9):e1000640. Epub 2009 Sep 11.
18. Utilization of genomic signatures to identify phenotype-specific drugs.S. Mori, J.T. Chang, E. R. Andrechek, A. Potti and J.R. Nevins. PLoS One. 2009 Aug 28; 4(8):e6772.
    
19. Anchorage-independent cell growth signature identifies tumors with metastatic potential.S. Mori, J.T. Chang, E.R. Andrechek, N. Matsumura, T. Baba, G. Yao, J.W. Kim, M.L. Gatza, S.Murphy and J.R. Nevins. Oncogene, Advance online publication, 1 June 2009; doi:10.1038/onc.2009.139.
20. Patterns of Cell Signaling Pathway Activation That Characterize Mammary Development E.R. Andrechek, S. Mori, J.T. Chang, R.E. Rempel and J.R. Nevins. Development, 2008 135(14):2403-2413.
21. Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. P.H. Giangrande, J. Zhang, A. Tanner, A.D. Eckhart, R.E. Rempel, E.R. Andrechek, J.M. Layzer, J.R. Keys, P.O. Hagen, J.R. Nevins, W.J. Koch and B.A. Sullenger. PNAS, 2007 104(32):12988-93.
22. Cell-type specific delivery of siRNAs with aptamer-siRNA chimeras. J.O. McNamara II*, E.R. Andrechek*, R.E. Rempel, E. Gilboa, B.A. Sullenger, P.H. Giangrande Nature Biotechnology, 2006 24(8):1005-15.* - authors contributed equally to this work.
23. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth. E.R. Andrechek, D. White and W.J. Muller Oncogene 2005 24(5):932-7.
24. Expression, Location and Interactions of ErbB2 and its Intramembrane Ligand Muc4 (Sialomucin Complex) in Rat Mammary Gland During Pregnancy S. A. Price, E.R. Andrechek, N. Idris, P. Li, M. Rong, J. Zhang, C.A.C. Carraway, W.J. Muller and K.L. Carraway Journal of Cellular Physiology 2005 203(1):44-53.
25. Germline expression of an oncogenic erbB2 allele confers resistance to erbB2 induced mammary tumorigenesis. E.R. Andrechek, W.R. Hardy, M.A. Laing and W.J. Muller PNAS, 2004 101(14):4984-9.
26. Gene expression profiling of Neu induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2 expressing human breast cancers.E.R. Andrechek, M.A. Laing, A.A. Girgis-Gabardo, P.M. Siegel and W.J. Muller Cancer Research, 2003 63(16):4920-6.
27. ErbB2 is Required for Muscle Spindle and Myoblast Cell Survival. E.R. Andrechek, W.R. Hardy, A. Girgis-Gabadro, R. Perry, R. Butler, F.L. Graham, R.C. Kahn, M.A. Rudnicki and W.J. Muller.Mol. Cell Biol. 2002 22(13):4714-22.
28. Mol. Cell Biol. Cover Illustration- 2003, 23(3)
29. Mol. Cell Biol. Cover Illustration- 2002, 22(14)
30. Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neudefine mouse mammary gland adenocarcinomas induced by mutant HER2/neu. C. Montagana, E.R. Andrechek, H. Padilla-Nash, W.J. Muller and T. Ried Oncogene 2002 21(6):890-8.
31. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. E.R. Andrechek, W.R. Hardy, P.M. Siegel, M.A. Rudnicki, R.D. Cardiff and W.J. Muller. PNAS, 2000 97(7):3444-9.
32. Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. M.J. Rauh, V. Blackmore, E.R. Andrechek, C.G. Tortorice, R. Daly, V.K. Lai, T. Pawson, R.D. Cardiff, P.M. Siegel and W.J. Muller. Mol. Cell Biol.1999 19(12):8169-79
33. Developmental Timing of Activated erbB2 Expression Plays a Critical Role in the Induction of Mammary Tumors. (Invited Review). E.R Andrechek and W.J. Muller  Cell Cycle 2004 Sep1;3(9).
34. Tyrosine kinase signaling in breast cancer: Tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. (Invited Review). E.R. Andrechek and W.J. Muller Breast Cancer Res.2000 2:211-216

Personal Profile